A dietary restriction influences the progression but not the initiation of MSG-induced nonalcoholic steatohepatitis

Makoto Fujimoto, Koichi Tsuneyama, Yuko Nakanishi, Thucydides L. Salunga, Kazuhiro Nomoto, Yoshiyuki Sasaki, Seiichi Iizuka, Mitsunobu Nagata, Wataru Suzuki, Tsutomu Shimada, Masaki Aburada, Yutaka Shimada, M. Eric Gershwin, Carlo Selmi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The metabolic syndrome is a major worldwide health care issue and a dominant risk factor for cardiovascular disease. The liver manifestations of this syndrome include nonalcoholic fatty liver disease (NAFLD) and its progressive variant nonalcoholic steatohepatitis (NASH). Although significant research has been performed, the basic pathogenesis of NAFLD/NASH remains controversial and effective treatments are still unavailable. We have previously reported on a murine model of NASH induced by the neonatal injection of monosodium glutamate (MSG), which includes the clinical manifestations of central obesity, diabetes, hyperlipidemia, and ultimately liver inflammation, fibrosis, and cancer. Although MSG is considered a safe food additive, its administration to pregnant rats increases the voracity and growth hormone levels in the offspring. To further understand the biology of this model, we have investigated the influence of the calorie intake on these clinical manifestations by feeding animals a restrictive diet. MSG-treated animals fed a restrictive diet continue to manifest obesity and early stage NASH but have improvements in serum lipid profiles. At 12 months of age, mice had manifestations of obesity, whether animals were fed a restricted or control diet, but animals fed a restrictive diet had a reduction in the progression of NASH. In conclusion, MSG appears to be a critical factor in the initiation of obesity, whereas calorie intake may modulate the progression of disease.

Original languageEnglish (US)
Pages (from-to)374-383
Number of pages10
JournalJournal of Medicinal Food
Volume17
Issue number3
DOIs
StatePublished - Mar 1 2014

Fingerprint

Sodium Glutamate
Diet
Obesity
Peptide Initiation Factors
Food Additives
Abdominal Obesity
Liver Neoplasms
Non-alcoholic Fatty Liver Disease
Hyperlipidemias
Liver Cirrhosis
Growth Hormone
Disease Progression
Cardiovascular Diseases
Inflammation
Delivery of Health Care
Lipids
Injections
Liver
Serum
Research

Keywords

  • diabetes
  • functional foods
  • hepatocellular carcinoma
  • metabolic syndrome
  • nonalcoholic fatty liver disease

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Fujimoto, M., Tsuneyama, K., Nakanishi, Y., Salunga, T. L., Nomoto, K., Sasaki, Y., ... Selmi, C. (2014). A dietary restriction influences the progression but not the initiation of MSG-induced nonalcoholic steatohepatitis. Journal of Medicinal Food, 17(3), 374-383. https://doi.org/10.1089/jmf.2012.0029

A dietary restriction influences the progression but not the initiation of MSG-induced nonalcoholic steatohepatitis. / Fujimoto, Makoto; Tsuneyama, Koichi; Nakanishi, Yuko; Salunga, Thucydides L.; Nomoto, Kazuhiro; Sasaki, Yoshiyuki; Iizuka, Seiichi; Nagata, Mitsunobu; Suzuki, Wataru; Shimada, Tsutomu; Aburada, Masaki; Shimada, Yutaka; Gershwin, M. Eric; Selmi, Carlo.

In: Journal of Medicinal Food, Vol. 17, No. 3, 01.03.2014, p. 374-383.

Research output: Contribution to journalArticle

Fujimoto, M, Tsuneyama, K, Nakanishi, Y, Salunga, TL, Nomoto, K, Sasaki, Y, Iizuka, S, Nagata, M, Suzuki, W, Shimada, T, Aburada, M, Shimada, Y, Gershwin, ME & Selmi, C 2014, 'A dietary restriction influences the progression but not the initiation of MSG-induced nonalcoholic steatohepatitis', Journal of Medicinal Food, vol. 17, no. 3, pp. 374-383. https://doi.org/10.1089/jmf.2012.0029
Fujimoto, Makoto ; Tsuneyama, Koichi ; Nakanishi, Yuko ; Salunga, Thucydides L. ; Nomoto, Kazuhiro ; Sasaki, Yoshiyuki ; Iizuka, Seiichi ; Nagata, Mitsunobu ; Suzuki, Wataru ; Shimada, Tsutomu ; Aburada, Masaki ; Shimada, Yutaka ; Gershwin, M. Eric ; Selmi, Carlo. / A dietary restriction influences the progression but not the initiation of MSG-induced nonalcoholic steatohepatitis. In: Journal of Medicinal Food. 2014 ; Vol. 17, No. 3. pp. 374-383.
@article{7c58a6f26c7b4c31b91fcbeaed13b5d0,
title = "A dietary restriction influences the progression but not the initiation of MSG-induced nonalcoholic steatohepatitis",
abstract = "The metabolic syndrome is a major worldwide health care issue and a dominant risk factor for cardiovascular disease. The liver manifestations of this syndrome include nonalcoholic fatty liver disease (NAFLD) and its progressive variant nonalcoholic steatohepatitis (NASH). Although significant research has been performed, the basic pathogenesis of NAFLD/NASH remains controversial and effective treatments are still unavailable. We have previously reported on a murine model of NASH induced by the neonatal injection of monosodium glutamate (MSG), which includes the clinical manifestations of central obesity, diabetes, hyperlipidemia, and ultimately liver inflammation, fibrosis, and cancer. Although MSG is considered a safe food additive, its administration to pregnant rats increases the voracity and growth hormone levels in the offspring. To further understand the biology of this model, we have investigated the influence of the calorie intake on these clinical manifestations by feeding animals a restrictive diet. MSG-treated animals fed a restrictive diet continue to manifest obesity and early stage NASH but have improvements in serum lipid profiles. At 12 months of age, mice had manifestations of obesity, whether animals were fed a restricted or control diet, but animals fed a restrictive diet had a reduction in the progression of NASH. In conclusion, MSG appears to be a critical factor in the initiation of obesity, whereas calorie intake may modulate the progression of disease.",
keywords = "diabetes, functional foods, hepatocellular carcinoma, metabolic syndrome, nonalcoholic fatty liver disease",
author = "Makoto Fujimoto and Koichi Tsuneyama and Yuko Nakanishi and Salunga, {Thucydides L.} and Kazuhiro Nomoto and Yoshiyuki Sasaki and Seiichi Iizuka and Mitsunobu Nagata and Wataru Suzuki and Tsutomu Shimada and Masaki Aburada and Yutaka Shimada and Gershwin, {M. Eric} and Carlo Selmi",
year = "2014",
month = "3",
day = "1",
doi = "10.1089/jmf.2012.0029",
language = "English (US)",
volume = "17",
pages = "374--383",
journal = "Journal of Medicinal Food",
issn = "1096-620X",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - A dietary restriction influences the progression but not the initiation of MSG-induced nonalcoholic steatohepatitis

AU - Fujimoto, Makoto

AU - Tsuneyama, Koichi

AU - Nakanishi, Yuko

AU - Salunga, Thucydides L.

AU - Nomoto, Kazuhiro

AU - Sasaki, Yoshiyuki

AU - Iizuka, Seiichi

AU - Nagata, Mitsunobu

AU - Suzuki, Wataru

AU - Shimada, Tsutomu

AU - Aburada, Masaki

AU - Shimada, Yutaka

AU - Gershwin, M. Eric

AU - Selmi, Carlo

PY - 2014/3/1

Y1 - 2014/3/1

N2 - The metabolic syndrome is a major worldwide health care issue and a dominant risk factor for cardiovascular disease. The liver manifestations of this syndrome include nonalcoholic fatty liver disease (NAFLD) and its progressive variant nonalcoholic steatohepatitis (NASH). Although significant research has been performed, the basic pathogenesis of NAFLD/NASH remains controversial and effective treatments are still unavailable. We have previously reported on a murine model of NASH induced by the neonatal injection of monosodium glutamate (MSG), which includes the clinical manifestations of central obesity, diabetes, hyperlipidemia, and ultimately liver inflammation, fibrosis, and cancer. Although MSG is considered a safe food additive, its administration to pregnant rats increases the voracity and growth hormone levels in the offspring. To further understand the biology of this model, we have investigated the influence of the calorie intake on these clinical manifestations by feeding animals a restrictive diet. MSG-treated animals fed a restrictive diet continue to manifest obesity and early stage NASH but have improvements in serum lipid profiles. At 12 months of age, mice had manifestations of obesity, whether animals were fed a restricted or control diet, but animals fed a restrictive diet had a reduction in the progression of NASH. In conclusion, MSG appears to be a critical factor in the initiation of obesity, whereas calorie intake may modulate the progression of disease.

AB - The metabolic syndrome is a major worldwide health care issue and a dominant risk factor for cardiovascular disease. The liver manifestations of this syndrome include nonalcoholic fatty liver disease (NAFLD) and its progressive variant nonalcoholic steatohepatitis (NASH). Although significant research has been performed, the basic pathogenesis of NAFLD/NASH remains controversial and effective treatments are still unavailable. We have previously reported on a murine model of NASH induced by the neonatal injection of monosodium glutamate (MSG), which includes the clinical manifestations of central obesity, diabetes, hyperlipidemia, and ultimately liver inflammation, fibrosis, and cancer. Although MSG is considered a safe food additive, its administration to pregnant rats increases the voracity and growth hormone levels in the offspring. To further understand the biology of this model, we have investigated the influence of the calorie intake on these clinical manifestations by feeding animals a restrictive diet. MSG-treated animals fed a restrictive diet continue to manifest obesity and early stage NASH but have improvements in serum lipid profiles. At 12 months of age, mice had manifestations of obesity, whether animals were fed a restricted or control diet, but animals fed a restrictive diet had a reduction in the progression of NASH. In conclusion, MSG appears to be a critical factor in the initiation of obesity, whereas calorie intake may modulate the progression of disease.

KW - diabetes

KW - functional foods

KW - hepatocellular carcinoma

KW - metabolic syndrome

KW - nonalcoholic fatty liver disease

UR - http://www.scopus.com/inward/record.url?scp=84896902437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896902437&partnerID=8YFLogxK

U2 - 10.1089/jmf.2012.0029

DO - 10.1089/jmf.2012.0029

M3 - Article

C2 - 24588719

AN - SCOPUS:84896902437

VL - 17

SP - 374

EP - 383

JO - Journal of Medicinal Food

JF - Journal of Medicinal Food

SN - 1096-620X

IS - 3

ER -